Can GSTP1 rs1695 AG, elevated ferritin, and low CoQ10 weaken antioxidant defenses?

The body’s defense against oxidative damage relies on an integrated network of enzymatic detoxification, iron regulation, and mitochondrial buffering.

Genetic and clinical biomarkers

• GSTP1 rs1695 AG variation: This heterozygous genotype causes an isoleucine-to-valine substitution at codon 105 (Ile105Val) near the catalytic center. This substitution moderately reduces glutathione-S-transferase activity and glutathione-conjugating capacity for standard electrophiles, such as 1-chloro-2,4-dinitrobenzene (CDNB).
• Elevated ferritin: Clinically, high ferritin levels correlate with increased lipid peroxidation markers, including malondialdehyde (MDA) and F2-isoprostanes, as well as the DNA damage marker 8-OHdG, signaling systemic iron-related stress.

Mechanistic pathways

• Labile iron pool expansion: Pathological saturation or degradation of ferritin expands the intracellular labile iron pool (LIP). Redox-active Fe²⁺ within the LIP drives Fenton and Haber-Weiss reactions, generating highly reactive hydroxyl radicals.
• Mitochondrial lipid peroxidation: Ubiquinol (reduced CoQ10) acts as a critical chain-breaking antioxidant in the inner mitochondrial membrane, scavenging lipid peroxyl radicals and regenerating alpha-tocopherol (vitamin E).
• The CoQ10 biphasic threshold: While severe deficiency halts electron transport, an intermediate CoQ10 deficiency (30–50% residual levels) preserves enough electron flux to generate reactive oxygen species but lacks the ubiquinol capacity to buffer them, driving peak lipid peroxidation.

Bottom line

• The GSTP1 rs1695 AG variant moderately reduces systemic conjugation capacity, while elevated ferritin increases free-radical-generating labile iron. When paired with low CoQ10, which compromises inner mitochondrial membrane lipid scavenging, these factors collectively undermine cellular and mitochondrial antioxidant defenses.